Psilocybin trials for depression yield mixed results, with new studies questioning their effectiveness compared to traditional treatments.
Psychedelics like psilocybin have gained attention in clinical research for potential treatments of depression and other conditions. According to MIT Technology Review, compounds such as psilocybin from magic mushrooms are being tested for depression, PTSD, addiction, and obesity, with scientific interest surging over the past decade.
Two recent studies focused on psilocybin's effectiveness for depression. In one German-based trial, 144 volunteers with treatment-resistant depression received either a high or low dose of psilocybin or an active placebo, combined with psychotherapy. The results showed some symptom improvement in the psilocybin group, but it was not significantly better than the placebo.
Study Details and Outcomes
The same study found that while psilocybin led to greater symptom reduction six weeks later, the authors described the findings as inconclusive due to inconsistencies. This highlights the difficulties in designing fair comparisons in psychedelic trials.
In the second study, led by Balázs Szigeti at UCSF, researchers analyzed open-label trials comparing psychedelics to traditional antidepressants. They determined that psychedelics were no more effective than standard drugs in reducing depressive symptoms.
Psychedelic trials face challenges with blinding, as participants can often tell if they received the drug due to its hallucinatory effects. Szigeti explained that this leads to a 'knowcebo effect,' where knowing one received a placebo can worsen outcomes, distorting results.
In traditional antidepressant trials, placebos reduce symptoms by about eight points on a scale, while the drugs add roughly two more points. For psychedelics, the placebo effect is weaker, at about four points, which can exaggerate perceived benefits. Szigeti noted that hype around psychedelics might amplify expectations and influence trial outcomes.
Despite underwhelming results, some researchers like Szigeti suggest that hype could enhance the placebo response, potentially aiding patients. However, he emphasized that the goal is patient improvement, regardless of the mechanism.
More Coverage
- Japanese Artist Yayoi Kusama Nears 100 with Major Retrospective in Cologne
- Ukraine Aids 5 Countries with Drone Expertise Against Iran Attacks, Zelenskyy States
- U.S. Regulators Reject Petition to Recall Tesla EVs Over One-Pedal Driving
- U.S. Accuses Iran of Running Hacktivist Group Behind Stryker Cyberattack
